PARIS - August 3, 2022 - (Newswire.com)
Tribun Health, the European leader in software development for digital pathology, is pleased to announce a strategic partnership with Mindpeak, a global leader for pathology AI software with world-class industry experts in the development of artificial intelligence algorithms to provide precision and speed in clinical pathology.
Together, Tribun Health and Mindpeak help pathologists analyze whole-slide-images (WSI) of immunohistochemically (IHC) stained human breast cancer tissue (biomarkers: Ki-67, ER and PR) to detect, classify, count cancer cells and to provide the respective quantitative score. This way, pathologists are relieved of tedious and repetitive tasks, which allows them to focus on the most complex cases where their expertise matters most. Tribun Health's Image Management System and Mindpeak's AI software are both CE-IVD marked, allowing their use as a medical device for clinical diagnostics and in research alike.
"As a provider of AI algorithms, we integrate our AI tools deeply into the leading pathology workflow platforms (IMS) available in order to provide the best user experience for pathologists and thereby a reproducible, accurate and quick diagnosis for the patients and their families. For this reason, we are very pleased to announce the integration of our breast cancer algorithms into CaloPix 5 by Tribun Health", says Felix Faber, CEO and Founder at Mindpeak.
It is also an alliance between two European companies looking to improve the way diagnosis is delivered by democratizing pathology with AI. "I am very excited about this strategic partnership. We are combining our fields of expertise to deliver ultimate clinical confidence and increased productivity. The integration and development of our catalog of the best third-party algorithms is an integral part of our end-to-end digital pathology suite, providing pathologists with a complete workflow for a high-value experience", says Jean-François Pomerol, CEO at Tribun Health. Mindpeak's algorithms are now available in the IMS CaloPix 5, ranked as Europe's top-performing digital pathology provider in 2022 by Klas Research, which is currently being deployed in various hospitals. Additional algorithms from Mindpeak, notably HER2 and PD-L1, will be integrated in a continuous mode.
About Mindpeak: Mindpeak, founded by Felix Faber and Dr. Tobias Lang, has been developing image analysis software for pathologists based on artificial intelligence since 2018. Partnering with several international laboratories and leading pathology service providers, Mindpeak is continuously expanding its product range and developing it into an indispensable component of the digitalised pathology workflow. Mindpeak's AI algorithms for breast cancer diagnosis were the first AI tools for digital pathology to make it into clinical routine in the USA.
Contact: Carsten Maltzan; PR Advisor; carsten.maltzan(@)mindpeak.ai
About Tribun Health: Tribun Health is a Paris-based company, addressing a significant and fast-growing need for end-to-end pathology department digitization. The privately held company is a pioneer in pathology workflow solutions and is considered the industry leader by winning the Best in Klas 2022 award for the most successful digital pathology provider in Europe. Tribun Health's extensive, decade-long expertise drives confidence for laboratories looking for a seamless transition to a digital pathology platform.
Contact: Lorine Marcoux; Marketing Manager; lmarcoux(@)tribun.health
Press Release Service by Newswire.com
Original Source: Tribun Health Enters a Strategic Partnership With Mindpeak to Provide Pathologists With the Most Advanced AI Diagnostic Tool for Breast Cancer
Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery has been awarded #1 on Newsweek's list of America's Best Plastic Surgeons 2022. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on June 15, 2022 and can currently be viewed on Newsweek's website.
America's Best Plastic Surgeons 2022 recognizes the best plastic surgeons in the U.S. concentrating on four major procedures: Breast Augmentation, Liposuction, Eyelid Surgery, Facelift, and Rhinoplasty. Statista invited over 2,000 medical experts (doctors/surgeons, plastic surgery clinic managers & health care professionals) to participate in an online survey. The rankings feature the top 150 plastic surgeons for Breast Augmentation, Liposuction, Facelift, and Rhinoplasty. 100 plastic surgeons were awarded for eyelid surgery. Our complex methodology ensures the quality and validity of the ranking. The evaluation process was comprised of two steps:
In-State and Out-of-State recommendations: an independent national survey which resulted in more than 5,900 recommendations from doctors/surgeons, plastic surgery clinic managers & health care professionals with knowledge of plastic surgery.
Quality Score: Additionally, participants were asked to rank the quality dimensions which influence the quality of plastic surgeons. Participants were asked to differentiate between these variables:
• Quality of care
• Continuity of care
• Quality of technical equipment
Certification: Plastic Surgeons receive a 5% bonus on their score if they have a American Board of Plastic Surgery (ABPS) certification
Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery is ecstatic to be recognized on Newsweek's list of America's Best Plastic Surgeons 2022.
Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery can be contacted via email, phone, website and Instagram.
4 Beauty Aesthetic Institute for Plastic Surgery
Dr. Constantino Mendieta
Press Release Service by Newswire.com
Original Source: Dr. Constantino Mendieta Awarded #1 on Newsweek's America's Best Plastic Surgeons 2022 List
Mira Ovum Wands
Mira launches Ovum Wand to detect FSH in urine
The FDA has listed Mira's new Mira Ovum Wand as an over-the-counter tool to detect the follicle-stimulating hormone (FSH) in urine. Starting October 2022, the product will be available to U.S. customers. The wands help monitor FSH levels to predict approaching menopause. They can also be used to monitor fertility and find possible causes of reproductive issues for women after 35.
Menopause has been a taboo subject for many generations. The lack of relevant education results in numerous misconceptions about this time in women's lives. Studies show that to this date, one-third of women do not research the topic before they experience menopause. A survey of 1,039 American women ages 40-65 finds that 45% of them didn't know the distinction between perimenopause and menopause. The Mira Ovum Wand can provide information to help understand perimenopause, predict menopause and address the symptoms early. FSH tracking can also help track the effectiveness of hormone replacement therapy to make it more targeted and personalized.
Tracking the follicle-stimulating hormone is essential for women in their 20s, 30s, or 40s because it directly impacts their ability to get pregnant. To predict approaching menopause or track changes in fertility, a person needs to test over several days for two or more cycles. Mira allows users to safely and regularly monitor their FSH levels at home without the need for constant and painful blood tests. And unlike FSH test strips, Mira provides lab-accurate numbers and data points that are saved and analyzed to give users personalized health insights. Users can also choose to share this data with their medical provider.
"The Mira Ovum Wand further expands our capabilities in at-home hormone testing. We can now provide accurate lab-like results for LH, E3G, PdG, and FSH. The launch reinforces Mira's goal to support women throughout their lives by helping them understand their hormones at any age, be it puberty, adulthood, or later years. This knowledge grants the ability to make informed fertility decisions and eliminates the dread associated with the word "menopause." So, women can go through this journey with confidence and awareness," says Sylvia Kang, CEO of Mira.
Mira offers a whole line of hormone test wands, including Mira Fertility (luteinizing hormone), Mira Fertility Plus (estrone-3-glucuronide and luteinizing hormone) and Mira Confirm (pregnanediol glucuronide). Like its predecessors, the new Mira Ovum Wand is compatible with the Mira Analyzer. This high-precision testing device uses machine learning to track changing hormone patterns over time, making Mira more effective than regular ovulation strips. The analyzer can be connected to Mira App to display clear numerical data along with personalized insights on the user's reproductive health.
Mira is the first at-home test to offer a personalized and lab-quality tracking system for monitoring women's reproductive health. It uses patented AI algorithms to accurately measure the levels of major hormones in a woman's urine to provide a holistic view of a woman's reproductive health. Mira is FDA-listed, clinically approved, and OB-GYN recommended.
For more information on Mira, please visit miracare.com.
Press contact: | [email protected] |
Press Release Service by Newswire.com
Original Source: Mira Launches Ovum Wand to Predict Menopause and Monitor Fertility Status for Women Over 35